Introduction: The importance of estimating the prognosis of advanced cancer patients is well known, but clinicians do not estimate survival time accurately. Since there is a need for an objective index to estimate survival time, the utility of the Prognostic Nutritional Index (PNI), which depends only on objective factors, was evaluated. Methods: The PNI was calculated using the following formula, PNI＝10×serum albumin value (g/dL)＋0.005×lymphocyte count in peripheral blood, at 3 months, 2 months, 1 month, 3 weeks, 2 weeks, 1 week, and within 3 days before death in 278 cancer patients (166 men, 112 women; age range, 33−99 years; mean age, 69.8 years) who died in a hospital surgical unit. Results: Sites of primary diseases included lung, breast, esophagus, stomach, colorectum, liver, biliary tract, and pancreas. The PNI values showed a gradual decrease over time. Changes in the PNI values were lower in non−gastrointestinal cancer patients than in gastrointestinal cancer patients. The mean PNI value was significantly higher in patients who lived ＞3 weeks (38.8) than in those who died within 3 weeks (32.4). When the PNI cut−off point was set at 35, and it was assumed that the life expectancy was within 3 weeks in cases with PNI ＜35, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 74.8％, 62.2％, 68.1％, and 69.6％, respectively. Discussion: The PNI appears to be a useful and simple parameter to predict clinical outcomes of patients with terminal stage cancer. Particularly, the PNI is considered feasible for gastrointestinal cancer patients. Palliat Care Res 2013; 8(2): 199−202
Introduction
The importance of estimating the prognosis of patients with advanced cancer has been widely recognized. Previous studies have shown that clinicians do not accurately estimate survival time 1, 2) . Systematic review of the accuracy of physicians' clinical predictions of survival in terminally ill cancer patients has shown that clinicians consistently overestimate survival, and their predictions are highly correlated with actual survival 3) . Various prognostic scores have been . It includes only objective indicators, using the values from regular blood test results. To date, the significance of the PNI as a marker for biological behavior has been mentioned in a few investigations [7] [8] [9] .
In this study, the feasibility of PNI as an index for estimating the prognosis of patients with terminal stage cancer was evaluated. Table 2 ). The mean PNI value of patients who lived more than 3 weeks was 38.8, while that of those who died within 3 weeks was 32.4; a significant difference was observed between the two groups ( Table 3) . When the cut−off point of PNI was set at 35, and it was assumed that the life expectancy was within 3 weeks in cases with a PNI less than 35, the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were 74.8％, 62.2％, 68.1％, and 69.6％, respectively.
Methods

Discussion
There have been various estimates of life expectancy for patients with terminal stage cancer 4, 5, 10) . For example, the PPS grades the clinical prediction of survival, anorexia, Karnofsky' s performance status (KPS), dyspnea, white blood cell count, and lymphocyte count. .
The PPI includes the existence of edema, dyspnea, and delirium, as well as subjective evaluation factors, such as the Palliative Performance Scale and amount of oral intake. A numeric partial score was given to each variable, and the sum of the single scores gives the total, which ranges from 0 to 15. If a patient has a grade of 6 or more points, life expectancy may be within 3 weeks, with sensitivity of 83％, specificity of 85％, PPV of 80％, and NPV of 87％. If a patient has a grade of 4 or more points, the sensitivity is 79％, specificity is 77％, PPV is 83％, and NPV is 71％ 5) .
These .
The PNI was initially designed by Buzby et al. 11) to assess the immunologic and nutritional aspects of patients undergoing surgical treatment for diseases of the digestive tract. However, the value could be calculated based on the measurement of many different parameters. The PNI used in the present study is also called Onodera' s PNI 6) .
It is an index that depends only on objective data (serum albumin level and peripheral lymphocyte count). The PNI was originally used in digestive surgery to evaluate patients' preoperative nutritional condition. In cases of grades below 40, anastomosis of the digestive tract was considered contraindicated. In addition, the PNI was considered to be a prognosis index in Stage Ⅳ cancer of the digestive tract. In 1986, the PNI was a predictive formula that could be used to estimate the possibility of death within 60 days when the patient was graded below 35. In this study, it was possible to predict a short prognosis on a weekly basis, but not for a longer duration of 60 days. However, it is clinically significant to predict a short prognosis on a weekly basis. If the cut−off value was set to be 40 in this study, the specificity decreased to 43.2％. Therefore, the PNI cutoff value has been set to be
35.
PNI is different from PPI, PPS and KPS. It is possible to be calculated automatically by computerized medical records system. It is also possible to be used as a common index in the same way as the screening and vital signs of patients in the terminal phase.
This study has a limitation. The present patients were not representative of a general population with advanced cancer. In fact, the patients did not include all cancer patients, because gastrointestinal cancer patients accounted for a large percentage. Changes in PNI val- . It is also possible that the patients who are taking steroid will have a low PNI value. Among our target cases, steroid was administered in 149 cases (53.6％). It is also possible that PNI fluctuated under the influence of steroid.
The PNI showed a lower value as time passed. Therefore, the PNI is considered feasible as a factor to predict clinical outcomes of patients with terminal stage cancer. This useful and simple parameter may be used to estimate the prognosis of patients with terminal stage cancer. Particularly, the PNI is considered feasible for gastrointestinal cancer patients. Others: None. 
